Werewolf Therapeutics HOWL Institutional Ownership

Updated Oct 11, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was held by 45 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Together they owned 22.36% of the outstanding stock in Q2 2026, down from 28.81% a quarter earlier.
• Total shares held in Werewolf Therapeutics fell 22.40% from Q1 2026, while the number of holders fell 29.69% from Q2 2025.
• Of the 45 holders, 18 added to their positions, 9 reduced their stakes and 18 left their positions unchanged in Q2 2026.
• Institutional investors held 10.86Mn shares of Werewolf Therapeutics in total at the end of Q2 2026, down 3.14Mn from the prior quarter and down 11.44Mn from a year earlier.
• Ra Capital Management, L.P. led 13F holders of HOWL with 2.39Mn shares as of June 30, 2026, or 4.91% of shares outstanding.
• Holders that added the most shares of Werewolf Therapeutics in Q2 2026 were Verdad Advisers, LP (+318.95K shares), XTX Topco Ltd (+220.55K shares), Jane Street Group, LLC (+169K shares), Renaissance Technologies LLC (+158.41K shares) and UBS Group AG (+148.98K shares).
• The largest position reductions in HOWL for Q2 2026 were by Ra Capital Management, L.P. (-4.29Mn shares), MPM BioImpact LLC (-1.13Mn shares), Millennium Management LLC (-70K shares), Geode Capital Management, LLC (-53.67K shares) and Simplex Trading, LLC (-32.27K shares).
• Per Business Quant data, the 10 largest holders of Werewolf Therapeutics at the end of Q2 2026 were Ra Capital Management, L.P. (2.39Mn shares), Balyasny Asset Management L.P. (1.79Mn shares), Vanguard Capital Management LLC (1.22Mn shares), Renaissance Technologies LLC (674.63K shares), Lynx1 Capital Management LP (657.79K shares), Sphera Funds Management LTD. (626.81K shares), DC Funds, LP (589.1K shares), Verdad Advisers, LP (348.71K shares), Geode Capital Management, LLC (335.81K shares) and Bank of America Corp (311.5K shares).